SAN DIEGO, Aug. 23 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM - News) today announced that it has named A. Michael Monko Senior Vice President of Sales and Marketing. Mr. Monko will lead the Company’s global sales growth and marketing initiatives.
Mr. Monko brings Sequenom 20 years of life science sales and marketing experience. Most recently he served as Vice-President of Sales for Upstate.Chemicon with global sales and management responsibility for more than 100 sales, service and support employees. Previously he served 19 years at Invitrogen Corporation with a progressive and accomplished career in sales, beginning as a representative and culminating as Senior Director, Sales Force Effectiveness.
“Mike is a seasoned executive with a history of building and leading successful sales and marketing teams, developing long-term customer relationships and delivering appreciable sales growth,” said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “We are pleased to welcome Mike to our management team and we look forward to the impact his leadership and experience will bring as we continue to build sales momentum and execute on our sales growth and marketing strategies.”
Mr. Monko earned his MBA from Babson College and BS in Biochemistry from University of New Hampshire.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for non-invasive prenatal testing, biomedical research, molecular medicine and agricultural applications. The Company’s proprietary MassARRAY® system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom® and MassARRAY® are trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the impact that Mr. Monko’s leadership and experience will bring to the Company, the Company’s sales momentum and the Company’s execution of its sales growth and marketing strategies, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s technologies, market acceptance of and demand for the Company’s products, reliance upon the collaborative efforts of others, product development and commercialization, and other risks detailed from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and subsequent current and periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Source: Sequenom, Inc.
